Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biden Promises 500 Million COVID-19 Tests As Omicron Threatens To Overwhelm US Health Care System

Executive Summary

The “President’s Winter Plan” to fight the new variant includes mailing out free COVID-19 take-home tests to Americans who ask for it. AdvaMed says it will encourage manufacturers to keep producing tests.

You may also be interested in...



Ordering Starts For Free OTC COVID-19 Tests; USPS Deliveries Expected Within Two Weeks

US consumers can order up to four rapid antigen tests per household through USPS website, or a phone hotline coming soon. Biden administration, which is working to buy another 500m tests soon, notes more OTC tests are becoming available through an accelerated pathway to support FDA reviews of for emergency use authorizations of tests with potential for large-scale manufacturing.

US Postal Service To Distribute Biden’s Free COVID-19 Rapid Antigen At-Home Tests Starting This Week

Americans can order up to four rapid antigen tests per household through the USPS website now, or a phone hotline soon. The administration is working to buy another half a billion tests in the near future.

Industry Urged White House To Invest In COVID-19 Tests Long Before Current Shortage: AdvaMed

The lobby group says the takeaway from the test shortage is the government should engage industry to prepare and ramp up test production before the next wave of variant infections in the ongoing pandemic.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

MT144870

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel